VTH148

VTH148 is a preclinical-stage drug candidate being developed by Verra Therapeutics. It is a peptide-based small protein, often referred to as a "mini-protein," derived from the company's proprietary drug discovery platform. While Verra Therapeutics has disclosed specific indications for other pipeline assets (such as COPD and myocardial infarction recovery), the exact molecular target and primary therapeutic indication for VTH148 have not yet been publicly released. The compound is part of a broader effort to utilize stable, high-affinity small proteins to modulate disease-relevant pathways in inflammatory and cardiovascular medicine.